… Comparative effects of gefitinib versus erlotinib on overall survival of patients with non-small
cell lung cancer. Results are presented as individual and pooled HRs with 95% CIs. A HR …

… with non-small cell lung cancer (NSCLC). We demonstrated that erlotinib and gefitinib have
similar … profiles, with a suggestion of better tolerability for gefitinib. The analysis suggests that …

… Erlotinib and gefitinib are tyrosine kinase (TK) inhibitors of epidermal growth factor receptor
(EGFR) that are effective in treating non-small cell lung cancer (NSCLC). This study aimed to …

… (250 mg daily gefitinib or 150 mg daily erlotinib) between April 2010 and March 2012 at
Kyoto University Hospital. Two of the 15 patients received gefitinib and erlotinib treatment; …

… A phase III trial was conducted to compare the safety and efficacy of erlotinib with that of
gefitinib in advanced non-small cell lung cancer harbouring epidermal growth factor receptor …

… Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC). Interstitial lung …

… –small cell lung cancer patients that develop resistance to gefitinib or erlotinib will contain a
secondary EGFR T790M mutation. As most patients do not undergo repeated tumor biopsies …

… If validated, our results suggest that gefitinib and erlotinib may have a role in the chemoprevention
of CNS metastases from NSCLC. Clin Cancer Res; 18(16); 4406–14. ©2012 AACR. …

… Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this … of gefitinib and
erlotinib was evaluated as the second-line therapy for advanced non-small cell lung cancer (…

… who were treated with gefitinib or erlotinib as their initial systemic therapy for advanced
NSCLC (18). Patients who were started on treatment with gefitinib or erlotinib from January 1, …